Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy

摘要

Background The role of remission status in limited disease (LD) small-cell lung cancer (SCLC) patients treated with definitive chemoradiotherapy (CRT) remains to be finally clarified. Methods Individual data from 184 patients treated with definitive CRT concurrently or sequentially were retrospectively reviewed. Kaplan-Meier analysis as well as univariate and multivariate Cox regression models were used to describe survival within patient subgroups defined by remission status. Results 71 (39?%) patients were treated in the concurrent, 113 (61?%) in the sequential CRT mode. Prophylactic cranial irradiation (PCI) was applied in 71 (39?%) patients. 37 (20?%) patients developed local, while 89 (48?%) distant recurrence. 58 (32?%) patients developed metachronous brain metastases. Complete, partial remission and non-response (defined as stable and progressive disease) were documented in 65 (35?%), 77 (42?%), and 37 (20?%) patients, respectively. In complete responders median overall survival was 21.8?months (95CI: 18.6 – 25) versus 14.9 (95?% CI: 11.7 – 18.2) ( p =?0.041, log-rank test) and 11.5?months (95?% CI: 8.9 – 15.0) ( p Conclusion In this treated heterogeneous LD SCLC patient cohort complete remission was associated with longer time to progression, distant metastasis-free and overall survival compared to the non- and especially partial responders.